{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:44:29Z","timestamp":1793324669288,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63554-4","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:23:05Z","timestamp":1759159385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A loss-of-function human ADAR variant activates innate immune response and promotes bowel inflammation"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-6040","authenticated-orcid":false,"given":"Pengfei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meishu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songrong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-9457","authenticated-orcid":false,"given":"Da","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingde","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-155X","authenticated-orcid":false,"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"63554_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","volume":"5","author":"V Jairath","year":"2020","unstructured":"Jairath, V. & Feagan, B. G. Global burden of inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 5, 2\u20133 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"63554_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"GBDIBD Collaborators","year":"2020","unstructured":"Collaborators, G. B. D. I. B. D. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 17\u201330 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"63554_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100544","volume":"27","author":"Y Qiu","year":"2020","unstructured":"Qiu, Y. et al. Disease burden of inflammatory bowel disease in China from 1990 to 2017: findings from the global burden of diseases 2017. EClinicalMedicine 27, 100544 (2020).","journal-title":"EClinicalMedicine"},{"key":"63554_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart, D. C. & Carding, S. R. Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627\u20131640 (2007).","journal-title":"Lancet"},{"key":"63554_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41575-019-0172-4","volume":"16","author":"YR Na","year":"2019","unstructured":"Na, Y. R., Stakenborg, M., Seok, S. H. & Matteoli, G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat. Rev. Gastroenterol. Hepatol. 16, 531\u2013543 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"63554_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41575-022-00634-6","volume":"19","author":"TH Bisgaard","year":"2022","unstructured":"Bisgaard, T. H., Allin, K. H., Keefer, L., Ananthakrishnan, A. N. & Jess, T. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nat. Rev. Gastroenterol. Hepatol. 19, 717\u2013726 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"63554_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41556-021-00708-8","volume":"23","author":"JV Patankar","year":"2021","unstructured":"Patankar, J. V. et al. E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis. Nat. Cell Biol. 23, 796\u2013807 (2021).","journal-title":"Nat. Cell Biol."},{"key":"63554_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S2468-1253(22)00021-8","volume":"7","author":"AN Ananthakrishnan","year":"2022","unstructured":"Ananthakrishnan, A. N. et al. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol. Hepatol. 7, 666\u2013678 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"63554_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41588-023-01384-0","volume":"55","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. Nat. Genet. 55, 796\u2013806 (2023).","journal-title":"Nat. Genet."},{"key":"63554_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.crohns.2009.12.008","volume":"4","author":"MB Bengtson","year":"2010","unstructured":"Bengtson, M. B., Aamodt, G., Vatn, M. H. & Harris, J. R. Concordance for IBD among twins compared to ordinary siblings-a Norwegian population-based study. J. Crohns Colitis 4, 312\u2013318 (2010).","journal-title":"J. Crohns Colitis"},{"key":"63554_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.gastro.2023.03.238","volume":"165","author":"AJ Noble","year":"2023","unstructured":"Noble, A. J., Nowak, J. K., Adams, A. T., Uhlig, H. H. & Satsangi, J. Defining interactions between the genome, epigenome, and the environment in inflammatory bowel disease: progress and prospects. Gastroenterology 165, 44\u201360 (2023).","journal-title":"Gastroenterology"},{"key":"63554_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119\u2013124 (2012).","journal-title":"Nature"},{"key":"63554_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s41588-022-01156-2","volume":"54","author":"A Sazonovs","year":"2022","unstructured":"Sazonovs, A. et al. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn\u2019s disease susceptibility. Nat. Genet. 54, 1275\u20131283 (2022).","journal-title":"Nat. Genet."},{"key":"63554_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-biochem-060208-105251","volume":"79","author":"K Nishikura","year":"2010","unstructured":"Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 79, 321\u2013349 (2010).","journal-title":"Annu. Rev. Biochem."},{"key":"63554_CR15","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41556-022-00959-z","volume":"24","author":"X Hao","year":"2022","unstructured":"Hao, X. et al. ADAR1 downregulation by autophagy drives senescence independently of RNA editing by enhancing p16(INK4a) levels. Nat. Cell Biol. 24, 1202\u20131210 (2022).","journal-title":"Nat. Cell Biol."},{"key":"63554_CR16","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.celrep.2014.10.041","volume":"9","author":"NM Mannion","year":"2014","unstructured":"Mannion, N. M. et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 9, 1482\u20131494 (2014).","journal-title":"Cell Rep."},{"key":"63554_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41586-022-05052-x","volume":"608","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. RNA editing underlies genetic risk of common inflammatory diseases. Nature 608, 569\u2013577 (2022).","journal-title":"Nature"},{"key":"63554_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.2414","volume":"44","author":"GI Rice","year":"2012","unstructured":"Rice, G. I. et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat. Genet. 44, 1243\u20131248 (2012).","journal-title":"Nat. Genet."},{"key":"63554_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ng.2933","volume":"46","author":"GI Rice","year":"2014","unstructured":"Rice, G. I. et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat. Genet. 46, 503\u2013509 (2014).","journal-title":"Nat. Genet."},{"key":"63554_CR20","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1126\/science.290.5497.1765","volume":"290","author":"Q Wang","year":"2000","unstructured":"Wang, Q., Khillan, J., Gadue, P. & Nishikura, K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science 290, 1765\u20131768 (2000).","journal-title":"Science"},{"key":"63554_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0370-3","volume":"13","author":"LA Crews","year":"2015","unstructured":"Crews, L. A. et al. An RNA editing fingerprint of cancer stem cell reprogramming. J. Transl. Med. 13, 52 (2015).","journal-title":"J. Transl. Med."},{"key":"63554_CR22","doi-asserted-by":"crossref","unstructured":"Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021).","DOI":"10.1126\/sciadv.abh2169"},{"key":"63554_CR23","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41586-022-04974-w","volume":"607","author":"R de Reuver","year":"2022","unstructured":"de Reuver, R. et al. ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation. Nature 607, 784\u2013789 (2022).","journal-title":"Nature"},{"key":"63554_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2249.2006.03214.x","volume":"146","author":"R Ito","year":"2006","unstructured":"Ito, R. et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 146, 330\u2013338 (2006).","journal-title":"Clin. Exp. Immunol."},{"key":"63554_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fmed.2019.00334","volume":"6","author":"HCK Angus","year":"2019","unstructured":"Angus, H. C. K., Butt, A. G., Schultz, M. & Kemp, R. A. Intestinal organoids as a tool for inflammatory bowel disease research. Front. Med. 6, 334 (2019).","journal-title":"Front. Med."},{"key":"63554_CR26","doi-asserted-by":"publisher","first-page":"10867","DOI":"10.1021\/ja029742d","volume":"125","author":"EA Veliz","year":"2003","unstructured":"Veliz, E. A., Easterwood, L. M. & Beal, P. A. Substrate analogues for an RNA-editing adenosine deaminase: mechanistic investigation and inhibitor design. J. Am. Chem. Soc. 125, 10867\u201310876 (2003).","journal-title":"J. Am. Chem. Soc."},{"key":"63554_CR27","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1053\/j.gastro.2022.07.081","volume":"163","author":"K Ishikawa","year":"2022","unstructured":"Ishikawa, K. et al. Identification of quiescent LGR5(+) stem cells in the human colon. Gastroenterology 163, 1391\u20131406.e1324 (2022).","journal-title":"Gastroenterology"},{"key":"63554_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2017.12.038","volume":"172","author":"H Chung","year":"2018","unstructured":"Chung, H. et al. Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell 172, 811\u2013824.e814 (2018).","journal-title":"Cell"},{"key":"63554_CR29","first-page":"1419","volume":"21","author":"W Wang","year":"2015","unstructured":"Wang, W. et al. Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria. Inflamm. Bowel Dis. 21, 1419\u20131427 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"63554_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41586-020-2127-x","volume":"580","author":"R Wang","year":"2020","unstructured":"Wang, R. et al. Gut stem cell necroptosis by genome instability triggers bowel inflammation. Nature 580, 386\u2013390 (2020).","journal-title":"Nature"},{"key":"63554_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.immuni.2015.11.001","volume":"43","author":"K Pestal","year":"2015","unstructured":"Pestal, K. et al. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development. Immunity 43, 933\u2013944 (2015).","journal-title":"Immunity"},{"key":"63554_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1101\/gr.124107.111","volume":"22","author":"JH Bahn","year":"2012","unstructured":"Bahn, J. H. et al. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res. 22, 142\u2013150 (2012).","journal-title":"Genome Res."},{"key":"63554_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36\u201349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"63554_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","volume":"17","author":"A Salas","year":"2020","unstructured":"Salas, A. et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 17, 323\u2013337 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"63554_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1053\/gast.2000.8520","volume":"119","author":"J Park","year":"2000","unstructured":"Park, J., Schulz, S. & Waldman, S. A. Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2. Gastroenterology 119, 89\u201396 (2000).","journal-title":"Gastroenterology"},{"key":"63554_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112733","volume":"42","author":"X Guo","year":"2023","unstructured":"Guo, X. et al. ADAR1 Zalpha domain P195A mutation activates the MDA5-dependent RNA-sensing signaling pathway in brain without decreasing overall RNA editing. Cell Rep. 42, 112733 (2023).","journal-title":"Cell Rep."},{"key":"63554_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.125","volume":"4","author":"W Qiu","year":"2013","unstructured":"Qiu, W. et al. ADAR1 is essential for intestinal homeostasis and stem cell maintenance. Cell Death Dis. 4, e599 (2013).","journal-title":"Cell Death Dis."},{"key":"63554_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1665","volume":"13","author":"B Song","year":"2022","unstructured":"Song, B., Shiromoto, Y., Minakuchi, M. & Nishikura, K. The role of RNA editing enzyme ADAR1 in human disease. Wiley Interdiscip. Rev. RNA 13, e1665 (2022).","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"63554_CR39","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1073\/pnas.1919028117","volume":"117","author":"SEJ Fischer","year":"2020","unstructured":"Fischer, S. E. J. & Ruvkun, G. Caenorhabditis elegans ADAR editing and the ERI-6\/7\/MOV10 RNAi pathway silence endogenous viral elements and LTR retrotransposons. Proc. Natl. Acad. Sci. USA 117, 5987\u20135996 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"63554_CR40","doi-asserted-by":"publisher","first-page":"20842","DOI":"10.1073\/pnas.0911267106","volume":"106","author":"T Saitoh","year":"2009","unstructured":"Saitoh, T. et al. Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc. Natl. Acad. Sci. USA 106, 20842\u201320846 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"63554_CR41","doi-asserted-by":"crossref","unstructured":"AlDaif, B. A., Mercer, A. A. & Fleming, S. B. The parapoxvirus Orf virus inhibits dsDNA-mediated type I IFN expression via STING-dependent and STING-independent signalling pathways. J. Gen. Virol. 104, 001912 (2023).","DOI":"10.1099\/jgv.0.001912"},{"key":"63554_CR42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/ecco-jcc\/jjac186","volume":"17","author":"K Takahashi","year":"2023","unstructured":"Takahashi, K. et al. RNA editing is a valuable biomarker for predicting carcinogenesis in ulcerative colitis. J. Crohns Colitis 17, 754\u2013766 (2023).","journal-title":"J. Crohns Colitis"},{"key":"63554_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino, A. V., Kanno, Y. & O\u2019Shea, J. J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat. Immunol. 18, 374\u2013384 (2017).","journal-title":"Nat. Immunol."},{"key":"63554_CR44","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.3748\/wjg.v26.i28.4055","volume":"26","author":"F Cordes","year":"2020","unstructured":"Cordes, F., Foell, D., Ding, J. N., Varga, G. & Bettenworth, D. Differential regulation of JAK\/STAT-signaling in patients with ulcerative colitis and Crohn\u2019s disease. World J. Gastroenterol. 26, 4055\u20134075 (2020).","journal-title":"World J. Gastroenterol."},{"key":"63554_CR45","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723\u20131736 (2017).","journal-title":"N. Engl. J. Med."},{"key":"63554_CR46","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn, W. J. et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease. Gastroenterology 158, 2123\u20132138.e2128 (2020).","journal-title":"Gastroenterology"},{"key":"63554_CR47","doi-asserted-by":"crossref","unstructured":"Dudek, P., Fabisiak, A., Zatorski, H., Malecka-Wojciesko, E. & Talar-Wojnarowska, R. Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment. J. Clin. Med. 10, 5660 (2021).","DOI":"10.3390\/jcm10235660"},{"key":"63554_CR48","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"key":"63554_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","volume":"145","author":"BS Kim","year":"2020","unstructured":"Kim, B. S. et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream. J. Allergy Clin. Immunol. 145, 572\u2013582 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"63554_CR50","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/S0140-6736(20)32469-7","volume":"396","author":"SK Uppal","year":"2020","unstructured":"Uppal, S. K., Kearns, D. G., Chat, V. S. & Wu, J. J. Ruxolitinib cream for the treatment of vitiligo. Lancet 396, 1735\u20131736 (2020).","journal-title":"Lancet"},{"key":"63554_CR51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan, D. P., Pope, J. E., Gotlib, J. & Harrison, C. N. Current and future status of JAK inhibitors. Lancet 398, 803\u2013816 (2021).","journal-title":"Lancet"},{"key":"63554_CR52","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426\u2013435 (2015).","journal-title":"N. Engl. J. Med."},{"key":"63554_CR53","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.cell.2012.11.048","volume":"152","author":"B Wu","year":"2013","unstructured":"Wu, B. et al. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell 152, 276\u2013289 (2013).","journal-title":"Cell"},{"key":"63554_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02646-0","volume":"19","author":"X Guo","year":"2022","unstructured":"Guo, X. et al. An AGS-associated mutation in ADAR1 catalytic domain results in early-onset and MDA5-dependent encephalopathy with IFN pathway activation in the brain. J. Neuroinflamm. 19, 285 (2022).","journal-title":"J. Neuroinflamm."},{"key":"63554_CR55","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1016\/j.immuni.2021.08.022","volume":"54","author":"T Nakahama","year":"2021","unstructured":"Nakahama, T. et al. Mutations in the adenosine deaminase ADAR1 that prevent endogenous Z-RNA binding induce Aicardi-Goutieres-syndrome-like encephalopathy. Immunity 54, 1976\u20131988 e1977 (2021).","journal-title":"Immunity"},{"key":"63554_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109500","volume":"36","author":"R de Reuver","year":"2021","unstructured":"de Reuver, R. et al. ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation. Cell Rep. 36, 109500 (2021).","journal-title":"Cell Rep."},{"key":"63554_CR57","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/emboj\/18.2.470","volume":"18","author":"M Schade","year":"1999","unstructured":"Schade, M., Turner, C. J., Lowenhaupt, K., Rich, A. & Herbert, A. Structure-function analysis of the Z-DNA-binding domain Zalpha of dsRNA adenosine deaminase type I reveals similarity to the (alpha + beta) family of helix-turn-helix proteins. EMBO J. 18, 470\u2013479 (1999).","journal-title":"EMBO J."},{"key":"63554_CR58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41431-019-0458-6","volume":"28","author":"A Herbert","year":"2020","unstructured":"Herbert, A. Mendelian disease caused by variants affecting recognition of Z-DNA and Z-RNA by the Zalpha domain of the double-stranded RNA editing enzyme ADAR. Eur. J. Hum. Genet. 28, 114\u2013117 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"63554_CR59","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1074\/jbc.M310162200","volume":"279","author":"Q Wang","year":"2004","unstructured":"Wang, Q. et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J. Biol. Chem. 279, 4952\u20134961 (2004).","journal-title":"J. Biol. Chem."},{"key":"63554_CR60","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1053\/j.gastro.2021.03.048","volume":"161","author":"P Xu","year":"2021","unstructured":"Xu, P. et al. Intestinal sulfation is essential to protect against colitis and colonic carcinogenesis. Gastroenterology 161, 271\u2013286 e211 (2021).","journal-title":"Gastroenterology"},{"key":"63554_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg9241","volume":"7","author":"Y Xi","year":"2021","unstructured":"Xi, Y. et al. The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1. Sci. Adv. 7, eabg9241 (2021).","journal-title":"Sci. Adv."},{"key":"63554_CR62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/gutjnl-2020-321339","volume":"70","author":"L Juznic","year":"2021","unstructured":"Juznic, L. et al. SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation. Gut 70, 485\u2013498 (2021).","journal-title":"Gut"},{"key":"63554_CR63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jcmgh.2023.05.003","volume":"16","author":"X Cai","year":"2023","unstructured":"Cai, X. et al. Inhibition of the SLC35B2-TPST2 axis of tyrosine sulfation attenuates the growth and metastasis of pancreatic ductal adenocarcinom. Cell Mol. Gastroenterol. Hepatol. 16, 473\u2013495 (2023).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"63554_CR64","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2021.12.260","volume":"162","author":"P Xu","year":"2022","unstructured":"Xu, P. et al. Inhibition of p53 sulfoconjugation prevents oxidative hepatotoxicity and acute liver failure. Gastroenterology 162, 1226\u20131241 (2022).","journal-title":"Gastroenterology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63554-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:04:04Z","timestamp":1759161844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63554-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63554"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63554-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8560"}}